American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 371-378 , September 2007

Is There a Role for Intensive Insulin Therapy in Patients With Kidney Disease?

Received 27 October 2006 ,Accepted 8 May 2007.

References 

  1. Van den Berghe G, Wilmer A, Hermans G. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–461
  2. Van den Berghe G, Wouters P, Weekers F. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–1367
  3. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus (DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group). BMJ. 1997;314:1512–1515
  4. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004;79:992–1000
  5. Goldberg P, Siegel M, Sherwin R, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care. 2004;27:461–467
  6. Metcalf W, Simpson M, Khan IH, et al. Scottish Renal Registry: Acute renal failure requiring renal replacement therapy: Incidence and outcome. QMJ. 2002;95:579–583
  7. Liano F, Pascual J. Madrid Acute Renal Failure Study Group: The spectrum of acute renal failure seen in the intensive care unit compared with that seen in other settings. Kidney Int. 1998;50:811–818
  8. Brivet FG, Kleinknecht D, Loirat P, Landais PJM. The French Study Group on Acute Renal Failure: Acute renal failure in intensive care units: Causes, outcome and prognostic factors of hospital mortality: A prospective multicenter study. Crit Care Med. 1996;24:192–198
  9. Carpentier YA, Scruel O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr Opin Clin Nutr Metab Care. 2002;5:153–158
  10. Mesotten D, Swinnen JV, Vanderhoydonc F, Wouters PJ, Van den Berghe G. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocrinol Metab. 2004;89:219–226
  11. Weekers F, Guiluetti AP, Michalaki M, et al. Metabolic, endocrine, and immune effects of stress hyperglycaemia in a rabbit model of prolonged critical illness. Endocrinology. 2003;144:5329–5338
  12. Van de Berghe G. Dynamic neuroendocrine responses to critical illness. Front Neuroendocrinol. 2002;23:370–391
  13. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycaemia. Crit Care Clin. 2001;17:107–124
  14. Khani S, Tayek JA. Cortisol increases gluconeogenesis in humans: Its role in the metabolic syndrome. Clin Sci. 2001;101:739–747(Lond)
  15. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care. 2002;5:551–559
  16. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol. 2002;90:11G–18G
  17. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care?. J Clin Invest. 2004;114:1187–1195
  18. Gordon BR, Parker TS, Levine DM, et al. Low lipid concentrations in critical illness: Implications for preventing and treating endotoxemia. Crit Care Med. 1996;24:584–589
  19. Gui D, Spada PL, De Gaetano A, Pacelli F. Hypocholesterolemia and risk of death in the critically ill surgical patient. Intensive Care Med. 1996;22:790–794
  20. Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61:284–289
  21. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care. 2005;28:810–815
  22. Frontera J, Fernandez A, Claassen J, et al. Hyperglycaemia after SAH: Predictors, associated complications, and impact on outcome. Stroke. 2006;37:199–203
  23. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: A systematic overview. Stroke. 2001;32:2426–2432
  24. Suleiman M, Hammerman H, Boulos M, et al. Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: A prospective study. Circulation. 2005;111:754–760
  25. Barsheshet A, Garty M, Grossman E, et al. Admission blood glucose level and mortality among hospitalized non-diabetic patients with heart failure. Arch Intern Med. 2006;166:1613–1619
  26. Rovlias A, Kotsou S. The influence of hyperglycemia on neurological outcome in patients with severe head injury. Neurosurgery. 2000;46:335–342
  27. Desai D, March R, Watters JM. Hyperglycemia after trauma increases with age. J Trauma. 1989;29:719–723
  28. Pekala P, Marlow M, Heuvelman D, Connolly D. Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. J Biol Chem. 1990;265:18051–18054
  29. Shikhman AR, Brinson DC, Valbracht J, Lotz MK. Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J Immunol. 2001;167:7001–7008
  30. Quinn LA, McCumbee WD. Regulation of glucose transport by angiotensin II and glucose in cultured vascular smooth muscle cells. J Cell Physiol. 1998;177:94–102
  31. Clerici C, Matthay MA. Hypoxia regulates gene expression of alveolar epithelial transport proteins. J Appl Physiol. 2000;88:1890–1896
  32. Sanchez-Alvarez R, Tabernero A, Medina JM. Endothelin-1 stimulates the translocation and upregulation of both glucose transporter and hexokinase in astrocytes: Relationship with gap junctional communication. J Neurochem. 2004;89:703–714
  33. Rao AK, Chouhan V, Chen X, et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes. 1999;48:1156–1161
  34. Black CT, Hennessey PJ, Andrassy RJ. Short-term hyperglycemia depresses immunity through nonenzymatic glycosylation of circulating immunoglobulin. J Trauma. 1990;30:830–832
  35. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves peri-operative outcomes and decreases recurrent ischemic events. Circulation. 2004;109:1497–1502
  36. Mak RHK, DeFronzo RA. Glucose and insulin metabolism in uraemia. Nephron. 1992;61:377–382
  37. Bagdade JD, Albers JJ. Plasma high density lipoprotein concentrations in chronic hemodialysis and renal transplant patients. N Engl J Med. 1977;296:1436–1439
  38. Harris HW, Grunfeld C, Feingold KR. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest. 1993;91:1028–1034
  39. Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet. 2005;365:53–59
  40. Jonassen A, Aasum E, Riemersma R, Mjos O, Larsen T. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther. 2000;14:615–623
  41. Malmberg K, Ryden L, Efendic S. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): Effects on mortality at one year. J Am Coll Cardiol. 1995;26:57–65
  42. Malmberg K, Efendic S, Ryden L. Feasibility of insulin-glucose infusion in diabetic patients with acute myocardial infarction (A report from the multicenter trial: DIGAMI). Diabetes Care. 1994;17:1007–1014

 Originally published online as doi: 10.1053/j.ajkd.2007.05.011 on July 5, 2007.

PII: S0272-6386(07)00834-7

doi: 10.1053/j.ajkd.2007.05.011

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 371-378 , September 2007

Article Tools

* Image Usage & Resolution